drugset
drugset / Trial / NCT05654181

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

NCT05654181 ↗

Phase 1 Completed 20 enrolled Pfizer
RandomizedCrossoverDouble-blindBasic science

Summary

This study is the first clinical study with PF-07328948. The safety, tolerability, and plasma pharmacokinetics and pharmacodynamics of PF-07328948 after administration of escalating, single, oral doses will be evaluated.

Timeline

Start
2022-10-17
Primary completion
2023-05-03
Completion
2023-05-03

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-07328948 Unknown — Oral

Indications

No indication recorded.